A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United ...

The New York Times: Ozempic's Next Magic Trick: Treating Drug Addiction Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...

Semaglutide and tirzepatides, the active ingredients in drugs including Mounjaro and Ozempic, have been hailed as a ...

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...

The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...